RARE logo

RARE Total Expenses

Annual Total Expenses

$1.00 B
-$8.79 M-0.87%

December 31, 2023


Summary


Performance

RARE Total Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRAREexpensesmetrics:

Quarterly Total Expenses

$271.48 M
+$8.09 M+3.07%

September 30, 2024


Summary


Performance

RARE Quarterly Total Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRAREexpensesmetrics:

Total Expenses Formula

Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses

RARE Total Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-0.9%+11.7%
3 y3 years+66.9%+58.3%
5 y5 years+137.3%+88.8%

RARE Total Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-0.9%+36.9%-14.0%+46.0%
5 y5-year-0.9%+90.1%-14.0%+117.6%
alltimeall time-0.9%>+9999.0%-14.0%+5703.4%

Ultragenyx Pharmaceutical Total Expenses History

DateAnnualQuarterly
Sep 2024
-
$271.48 M(+3.1%)
Jun 2024
-
$263.39 M(-3.9%)
Mar 2024
-
$274.18 M(+9.9%)
Dec 2023
$1.00 B(-0.9%)
$249.44 M(+2.6%)
Sep 2023
-
$243.15 M(-5.1%)
Jun 2023
-
$256.27 M(+0.7%)
Mar 2023
-
$254.60 M(+2.3%)
Dec 2022
$1.01 B(+38.1%)
$248.98 M(-21.2%)
Sep 2022
-
$315.77 M(+36.7%)
Jun 2022
-
$230.94 M(+6.6%)
Mar 2022
-
$216.57 M(+16.5%)
Dec 2021
$733.14 M(+22.0%)
$185.95 M(+8.4%)
Sep 2021
-
$171.47 M(+1.0%)
Jun 2021
-
$169.75 M(-17.6%)
Mar 2021
-
$205.96 M(+9.8%)
Dec 2020
$601.15 M(+13.9%)
$187.62 M(+42.4%)
Sep 2020
-
$131.78 M(+5.6%)
Jun 2020
-
$124.76 M(-20.5%)
Mar 2020
-
$156.97 M(+20.7%)
Dec 2019
$527.89 M(+24.8%)
$130.04 M(-9.6%)
Sep 2019
-
$143.83 M(+5.3%)
Jun 2019
-
$136.62 M(+16.4%)
Mar 2019
-
$117.39 M(+10.1%)
Dec 2018
$422.87 M
$106.60 M(+5.1%)
DateAnnualQuarterly
Sep 2018
-
$101.41 M(-5.8%)
Jun 2018
-
$107.69 M(+0.5%)
Mar 2018
-
$107.16 M(+8.0%)
Dec 2017
$331.55 M(+33.6%)
$99.25 M(+18.3%)
Sep 2017
-
$83.91 M(+7.0%)
Jun 2017
-
$78.44 M(+12.1%)
Mar 2017
-
$69.95 M(-0.9%)
Dec 2016
$248.14 M(+68.0%)
$70.55 M(+7.1%)
Sep 2016
-
$65.89 M(+13.5%)
Jun 2016
-
$58.07 M(+8.3%)
Mar 2016
-
$53.62 M(-4.5%)
Dec 2015
$147.74 M(+160.2%)
$56.16 M(+40.6%)
Sep 2015
-
$39.94 M(+32.5%)
Jun 2015
-
$30.14 M(+40.2%)
Mar 2015
-
$21.50 M(+26.9%)
Dec 2014
$56.78 M(+75.9%)
$16.94 M(+7.0%)
Sep 2014
-
$15.84 M(+15.9%)
Jun 2014
-
$13.66 M(+32.1%)
Mar 2014
-
$10.34 M(+8.5%)
Dec 2013
$32.28 M(+101.9%)
$9.53 M(+22.7%)
Sep 2013
-
$7.76 M(-5.9%)
Jun 2013
-
$8.25 M(+22.2%)
Mar 2013
-
$6.75 M(+44.2%)
Dec 2012
$15.98 M(+143.6%)
$4.68 M
Dec 2011
$6.56 M
-

FAQ

  • What is Ultragenyx Pharmaceutical annual total expenses?
  • What is the all time high annual total expenses for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical annual total expenses year-on-year change?
  • What is Ultragenyx Pharmaceutical quarterly total expenses?
  • What is the all time high quarterly total expenses for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical quarterly total expenses year-on-year change?

What is Ultragenyx Pharmaceutical annual total expenses?

The current annual total expenses of RARE is $1.00 B

What is the all time high annual total expenses for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high annual total expenses is $1.01 B

What is Ultragenyx Pharmaceutical annual total expenses year-on-year change?

Over the past year, RARE annual total expenses has changed by -$8.79 M (-0.87%)

What is Ultragenyx Pharmaceutical quarterly total expenses?

The current quarterly total expenses of RARE is $271.48 M

What is the all time high quarterly total expenses for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high quarterly total expenses is $315.77 M

What is Ultragenyx Pharmaceutical quarterly total expenses year-on-year change?

Over the past year, RARE quarterly total expenses has changed by +$28.33 M (+11.65%)